Target Price | $60.68 |
Price | $57.82 |
Potential |
4.95%
register free of charge
|
Number of Estimates | 19 |
19 Analysts have issued a price target Bristol-Myers Squibb 2026 .
The average Bristol-Myers Squibb target price is $60.68.
This is
4.95%
register free of charge
$70.00
21.07%
register free of charge
$37.00
36.01%
register free of charge
|
|
A rating was issued by 26 analysts: 7 Analysts recommend Bristol-Myers Squibb to buy, 18 to hold and 1 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Bristol-Myers Squibb stock has an average upside potential 2026 of
4.95%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Billion $ | 48.30 | 45.61 |
7.32% | 5.56% | |
EBITDA Margin | 39.98% | 41.63% |
1.59% | 4.13% | |
Net Margin | -18.53% | 24.80% |
206.46% | 233.87% |
22 Analysts have issued a sales forecast Bristol-Myers Squibb 2025 . The average Bristol-Myers Squibb sales estimate is
This results in the following potential growth metrics:
12 Analysts have issued an Bristol-Myers Squibb EBITDA forecast 2025. The average Bristol-Myers Squibb EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
11 Bristol-Myers Squibb Analysts have issued a net profit forecast 2025. The average Bristol-Myers Squibb net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -4.41 | 5.57 |
214.25% | 226.30% | |
P/E | 10.37 | |
EV/Sales | 3.46 |
11 Analysts have issued a Bristol-Myers Squibb forecast for earnings per share. The average Bristol-Myers Squibb EPS is
This results in the following potential growth metrics and future valuations:
Bristol-Myers Squibb...
Analyst | Rating | Action | Date |
---|---|---|---|
Wells Fargo |
Locked
➜
Locked
|
Locked | Feb 07 2025 |
Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Feb 04 2025 |
Citigroup |
Locked
➜
Locked
|
Locked | Jan 28 2025 |
Truist Securities |
Locked
➜
Locked
|
Locked | Jan 08 2025 |
Jefferies |
Locked
➜
Locked
|
Locked | Dec 16 2024 |
B of A Securities |
Locked
➜
Locked
|
Locked | Dec 10 2024 |
Wolfe Research |
Locked
➜
Locked
|
Locked | Nov 15 2024 |
Analyst Rating | Date |
---|---|
Locked
Wells Fargo:
Locked
➜
Locked
|
Feb 07 2025 |
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Feb 04 2025 |
Locked
Citigroup:
Locked
➜
Locked
|
Jan 28 2025 |
Locked
Truist Securities:
Locked
➜
Locked
|
Jan 08 2025 |
Locked
Jefferies:
Locked
➜
Locked
|
Dec 16 2024 |
Locked
B of A Securities:
Locked
➜
Locked
|
Dec 10 2024 |
Locked
Wolfe Research:
Locked
➜
Locked
|
Nov 15 2024 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.